Keyword Search
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/18/13Syros Pharmaceuticals Announces Publication of Important Scientific Studies Related to Company’s Industry-Leading Gene Control Platform
- Cancer Cell paper demonstrates a road map to tumor dependencies in lymph node cancer from Super-Enhancer analysis - - Nature Biotechnology paper describes novel ChemSeq technology, which allows for genome mapping of small molecules -WATERTOWN, MA, December 18, 2013 – Syros Pharmaceuticals, a life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases, announced today that papers recently published by Syros Scientific Founders... 
Printer Friendly Version
12/16/13Dr. Nathanael Gray, a Syros Pharmaceuticals Scientific Founder, Honored with 2013 Meyenburg Cancer Research Award
Dr. Gray recognized for developing first-in-class protein kinase inhibitorsfor cancer and other diseases WATERTOWN, MA, December 16, 2013 – Nathanael Gray, Ph.D., a scientific founder of Syros Pharmaceuticals and professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Dana-Farber Cancer Institute, was honored as the sole recipient of the prestigious 2013 Meyenburg Cancer Research Award. Gray was recognized for his groundbreaking work in developing f... 
Printer Friendly Version
11/21/13Syros Pharmaceuticals Appoints Stéphane Bancel to Board of Directors
WATERTOWN, MA, November 21, 2013 – Syros Pharmaceuticals, a life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases, announced today that Stéphane Bancel, President and Founding Chief Executive Officer (CEO) of Moderna Therapeutics, and Senior Partner at Flagship Ventures, has joined its Board of Directors. “I am excited to welcome Stéphane, an accomplished life sciences business leader and CEO to Syros’ Board of Di... 
Printer Friendly Version
10/10/13Syros Pharmaceuticals Announces New Findings on Central Role of Super-Enhancers in Controlling Cell Biology and Disease
- Cell paper describes presence of Super-Enhancers across multiple cell types and points to their utility as biomarkers - - Research further supports Syros’ Super-Enhancer platform for diagnostic and therapeutic applications -WATERTOWN, MA, October 10, 2013 – Syros Pharmaceuticals, a life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases, today announced the publication of new findings about the central role of rece... 
Printer Friendly Version
09/05/13Syros Pharmaceuticals Appoints Vicki L. Sato, Ph.D., to Board of Directors
WATERTOWN, MA, September 5, 2013 – Syros Pharmaceuticals, a life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases, announced today the appointment of Vicki L. Sato, Ph.D., to its Board of Directors. Dr. Sato is a Professor of Management Practice at Harvard Business School, and Professor of the Practice in the Department of Molecular and Cell Biology at Harvard University. She was previously President of Vertex Pharma... 
Printer Friendly Version
05/22/13Syros Pharmaceuticals Appoints Eric R. Olson, Ph.D. as Chief Scientific Officer
Dr. Olson’s Extensive Experience in Personalized Medicine Will Support Syros’ Mission to Lead in Gene Control WATERTOWN, MA, May 22, 2013 – Syros Pharmaceuticals, a newly launched company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases, announced today that Eric R. Olson, Ph.D., has joined the company as its Chief Scientific Officer. Dr. Olson has over 25 years experience in the life sciences industry, most recently as Research... 
Printer Friendly Version
04/15/13Syros: Super maps; BioCentury on BioBusiness. Cain, Chris
... 
Printer Friendly Version
04/12/13Super-powered switches may decide cell fate; Nature. Maxmen, Amy
... 
Printer Friendly Version
04/11/13Syros Pharmaceuticals Announces Publications in Cell Related to Key Gene Control Discovery
- Studies find Super-Enhancers control cell identity and drive cancer-causing genes; Syros holds exclusive licenses to Super-Enhancer intellectual property -WATERTOWN, MA, April 11, 2013 – Syros Pharmaceuticals, a newly launched company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases, today announced the publication of new research findings in the journal Cell. The research validates the approach of mapping and targeting newly identi... 
Printer Friendly Version
04/11/13Syros Pharmaceuticals Launches with $30 Million Series A Financing
- Company Founded Based on Leading Gene Control Science and Technologies,Co-founded by World-Leading Scientists and Top-Tier Life Sciences Venture Capital Firms - - Founders’ Data Describing Breakthrough Discoveries Published Today in Cell -WATERTOWN, MA, April 11, 2013 – Syros Pharmaceuticals, a newly launched company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases, today announced that it has completed a $30 million Series A fina... 
Printer Friendly Version
04/11/13Syros, a Whitehead and Dana-Farber Spinoff, Snags $30M For Cancer; Xconomy. Timmerman, Luke
... 
Printer Friendly Version
04/11/13Syros Pharma snags $30M funding deal to target master switches of cancer genes; FierceBiotech. McBride, Ryan
... 
Printer Friendly Version